Description
The MH3-2 monoclonal antibody specifically recognizes the human variable beta 5.2 (TCR Vβ5.2) and variable beta 5.3 (TCR Vβ5.3) domains of the beta subunit for the αβ T cell receptor (TCR Vβ5.2/5.3). The TCR Vβ5.2 and TCR Vβ5.3 domains are encoded by the TRBV5-6 (T cell receptor beta variable 5-6; also known as TCRBV5S2) and TRBV5-5 (T cell receptor beta variable 5-5; TCRBV5S3) gene segments of the multimembered Vβ5 subfamily within the TRB (T cell receptor beta locus), respectively. Functional T-cell receptor beta chains (TCR-β) are generated by genomic rearrangement of TCR variable (Vβ), diversity (Dβ), joining (Jβ) and constant (Cβ) region gene segments by precursor T cells. Distinct αβ TCR containing either TCR Vβ5.2 or TCR Vβ5.3 are clonally expressed on subsets of thymocytes or peripheral CD4+ or CD8+ T cells. These TCR β beta chains can heterodimerize with TCR α chains to form αβ TCR that function as signaling T cell receptors for antigen. Human αβ TCR recognize peptides presented by HLA (MHC) molecules and in conjunction with the associated CD3 complex, can transduce intracellular signals that initiate precursor or mature T cell responses. The MH3-2 antibody may be useful for analyzing the frequencies or numbers of TCR Vβ5.2/5.3-positive thymocytes or mature T cells as well as the levels of TCR Vβ5.2/5.3 expressed by these cells. The MH3-2 antibody can be used in research applications such as flow cytometry to help characterize the TCR Vβ repertoires of precursor or mature T cell populations.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant™ Violet 750 is covered by one or more of the following US patents: 8,158,444; 8,802,450; 8,575,303; 8,455,613; 8,227,187; 8,841,072; 8,110,673.
